Floatz logo

(1-743)-(1638-2332)-BLOOD-COAGULATION FACTOR VIII (SYNTHETIC HUMAN) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (SYNTHETIC HUMAN FC DOMAIN FRAGMENT), (1444-6'),(1447-9')-BIS(DISULFIDE) WITH IMMUNOGLOBULIN G1 (SYNTHETIC HUMAN FC DOMAIN FRAGMENT)

Severe Hemophilia A

Explore 10 assets in Severe Hemophilia A →
Floatz Rating
B59/100
Confidence
Indicative
v0.2
Sponsor
Margaret Ragni
Modality
protein_peptide
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
44Moderate confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT02196207CT.gov
Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform
—Withdrawn———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Severe Hemophilia A

AssetSponsorPhaseRating
(1-743)-(1638-2332)-BLOOD-COAGULATION FACTOR VIII (SYNTHETIC HUMAN) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (SYNTHETIC HUMAN FC DOMAIN FRAGMENT), (1444-6'),(1447-9')-BIS(DISULFIDE) WITH IMMUNOGLOBULIN G1 (SYNTHETIC HUMAN FC DOMAIN FRAGMENT) (this asset)Margaret RagniP3B · 59
Human Antihemophilic Factor/Von Willebrand Factor ComplexAryoGen Pharmed Co.P4BBB
EmicizumabChulalongkorn UniversityP4BBB
Human-Cl RhfviiiOctapharmaP3BBB
RfviiifcBioverativ Therapeutics Inc.P3BB
Alphanate Sd/HtGrifols Biologicals, LLCP4BB
Frsw117Hangzhou Gensciences Biopharmaceutical Co., Ltd.P3BB
AdvateHangzhou Gensciences Biopharmaceutical Co., Ltd.P3BB
Efanesoctocog AlfaSwedish Orphan BiovitrumP3BB

+13 more in the Severe Hemophilia A cohort

Other indications for (1-743)-(1638-2332)-BLOOD-COAGULATION FACTOR VIII (SYNTHETIC HUMAN) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (SYNTHETIC HUMAN FC DOMAIN FRAGMENT), (1444-6'),(1447-9')-BIS(DISULFIDE) WITH IMMUNOGLOBULIN G1 (SYNTHETIC HUMAN FC DOMAIN FRAGMENT)

IndicationSponsorPhaseRating
Hemophilia A—P4BB · 66
Hemophilia B—UnkD · 30

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. (1-743)-(1638-2332)-BLOOD-COAGULATION FACTOR VIII (SYNTHETIC HUMAN) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (SYNTHETIC HUMAN FC DOMAIN FRAGMENT), (1444-6'),(1447-9')-BIS(DISULFIDE) WITH IMMUNOGLOBULIN G1 (SYNTHETIC HUMAN FC DOMAIN FRAGMENT) in Severe Hemophilia A. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/1-743-1638-2332-blood-coagulation-factor-viii-synthetic-human-fusion-protein-with-immunoglobulin-g1-synthetic-human-fc-domain-fragment-1444-61447-9-bisdisulfide-with-immunoglobulin-g1-synthetic-human-fc-domain-fragment-severe-hemophilia-a

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →